RJA
CLVS

Raymond James & Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Raymond James & Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,897
Closed -$98K – 4257
2021
Q1 		$98K Buy
+13,897
New +$93.2K ﹤0.01% 3782
2017
Q3 		– Sell
-7,581
Closed -$710K – 3513
2017
Q2 		$710K Buy
7,581
+3,102
+69% +$190K ﹤0.01% 2228
2017
Q1 		$285K Sell
4,479
-2,544
-36% -$155K ﹤0.01% 2723
2016
Q4 		$312K Buy
7,023
+773
+12% +$27.2K ﹤0.01% 2602
2016
Q3 		$225K Buy
+6,250
New +$134K ﹤0.01% 2795

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return